Colonic mucosal eosinophilia and immunohistochemical expression of COX-2 and NF-kB in patients with irritable bowel syndrome

Eur J Gastroenterol Hepatol. 2022 May 1;34(5):512-517. doi: 10.1097/MEG.0000000000002363.

Abstract

Background: There is growing evidence that eosinophilic infiltration can release mediators which are harmful to the intestinal epithelium in patients with irritable bowel syndrome (IBS). Although cyclooxygenase 2 (COX-2) and nuclear factor-kappa beta (NF-kB) expression had been previously reported to increase in many inflammatory conditions, there is a paucity in data investigating their expressions in IBS. Our aim was to evaluate colonic mucosal eosinophilia and immunohistochemical expression of COX-2 and NF-kB in patients with irritable bowel syndrome.

Methods: A total of 80 patients who met the inclusion criteria of IBS based on Rome IV symptoms questionnaire were subjected to abdominal ultrasound, laboratory investigations, serum immunoglobulin E (IgE) level assessment and colonoscopic examination. Immunohistochemistry was performed to detect COX-2 and NF-kB expression in colonic biopsies obtained from IBS patients.

Results: Histopathological examination showed that 60 colonic biopsy specimens (75%) showed few mixed inflammatory cells ≤3 cells/ HPF, 12 biopsy specimens (15%) showed eosinophilic infiltration ≥25 eosinophils/HPF and 8 biopsy specimens (10%) showed severe lymphocytic infiltration and aggregation. Colonic eosinophilic infiltrate was significantly higher among patients presented with IBS-D subtype. Serum IgE was significantly higher among patients with colonic eosinophilic infiltrate than the others. In IBS-D patients, colonic mucosa showed positive expression of COX-2 and NF-kB in 52.1% and 81.25% of cases, respectively.

Conclusion: Patients with IBS -particularly IBS-D subtype- should undergo colonoscopy and biopsy to exclude underlying inflammatory pathology. Moreover, patients with positive COX-2 and NF-kB need further evaluation and follow-up.

MeSH terms

  • Colitis, Microscopic*
  • Cyclooxygenase 2* / metabolism
  • Diarrhea / metabolism
  • Enteritis
  • Eosinophilia* / pathology
  • Gastritis
  • Humans
  • Immunoglobulin E
  • Intestinal Mucosa / pathology
  • Irritable Bowel Syndrome* / diagnosis
  • Irritable Bowel Syndrome* / metabolism
  • NF-kappa B* / metabolism

Substances

  • NF-kappa B
  • Immunoglobulin E
  • Cyclooxygenase 2
  • PTGS2 protein, human

Supplementary concepts

  • Eosinophilic enteropathy